ARCHIVES

OMB Restrictions On Reprogramming Could Result In Inefficient Last Minute Spending By Institutes

This article is from The Cancer Letter archive.

Vol. 11 No. 35 | September 13, 1985

Download PDF Visit The Full Archive

Related Articles

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

July 27, 2001

Center For Health Policy And Outcomes Established At Memorial Sloan Kettering. ONS Marks 35th Year.

July 9, 2010

On Capitol Hill: Funding Outlook Brighter For NIH and NCI as appropriators Provide Increases

October 1, 1999

Avon 1995 Grant Application Available

December 2, 1994

FDA Approves Bexxar For Non-Hodgkin’s Lymphoma

June 27, 2003

FDA Approves Gleevec In 73 Days, A Speed Record.

May 18, 2001